Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25496787 | 0.91 | ADORA2A (0.44) | ADORA2AADORA3ADORA1ADORA2BCYP1A2 | |
| SCHEMBL8768130 | 0.90 | ADORA2A (0.56) | ADORA2AADORA3ADORA1ADORA2BCYP1A2 | |
| SCHEMBL1066408 | 0.90 | ADORA2A (0.53) | ADORA2AADORA3ADORA1ADORA2BCYP1A2 | |
| SCHEMBL14665042 | 0.90 | ADORA2A (0.53) | ADORA2AADORA3ADORA1ADORA2BCYP1A2 | |
| SCHEMBL14665046 | 0.90 | ADORA2A (0.53) | ADORA2AADORA3ADORA1ADORA2BCYP1A2 | |
| SCHEMBL8972045 | 0.86 | KDM4E (0.44) | ADORA3ADORA1 | |
| SCHEMBL30002219 | 0.86 | TYMP (0.56) | ADORA1 | |
| SCHEMBL25504326 | 0.84 | HINT1 (0.38) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL25496785 | 0.81 | ADORA2A (0.37) | ADORA2AADORA3ADORA1ADORA2BCYP1A2 | |
| SCHEMBL24703675 | 0.81 | ADORA3 (0.42) | ADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262859-A1 | CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME | UNIV TOKYO SCIENCE FOUND (JP) | 2024-08-08 | — | — | US | disclosed |
| EP-4349846-A1 | CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-117412983-A | Chimeric nucleic acid oligomer comprising phosphorothioate and borazine phosphate, and method for producing same | 学校法人东京理科大学 | 2024-01-16 | — | — | CN | disclosed |
| WO-2022255469-A1 | CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME | 学校法人東京理科大学 | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262859-A1 | CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME | RNGTT, NSUN2, MTAP | ADORA2A 173/4885ADORA3 69/4885ADORA1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.